Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novartis presents new PCSK9 inhibitors

June 11, 2020

Phase I data presented for URAT1 inhibitor D-0120

June 10, 2020

C12orf49 is new lipid metabolism gene

June 10, 2020

Soleno reports topline phase III results for DCCR as treatment of Prader-Willi syndrome

June 9, 2020

Pigv341E mice mimic glycosylphosphatidylinositol biosynthesis deficiency

June 9, 2020

Healthspan, lifespan affected differently by caloric restriction

June 9, 2020

Qilu Regor Therapeutics identifies GLP-1 receptor agonists

June 8, 2020

TES Pharma describes ACMSD inhibitors

June 8, 2020

First healthy volunteer dosed in phase I trial of ARCT-810

June 8, 2020

FDA places clinical hold on phase II/III trial of LYS-SAF-302 gene therapy for MPS IIIA

June 5, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...